{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.03","upperLimit":"1.83","value":"1.150"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Pharmacokinetics of Durvalumab derived from serum concentration versus time data.","dispersionType":"Full Range","groups":[{"description":"Durvalumab 1500 mg + Daratumumab 16 mg/kg were administered intravenously within a 28-day cycle for a maximum of 60 cycles.","id":"OG000","title":"Simon Stage 1: D2 Arm"}],"paramType":"MEDIAN","populationDescription":"All participants who received at least 1 dose of study medication and who have at least 1 measurable plasma concentration. Tmax was a pre-specified secondary outcome measure in the Simon Stage 1: D2 arm only.","reportingStatus":"POSTED","timeFrame":"Cycle 1 - Days 2, 8, 15, 22","title":"Time of Maximum Observed Concentration (Tmax) - Simon Stage 1: D2 Arm","type":"SECONDARY","unitOfMeasure":"Hour"}